1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer : Analysis of Pain and Fatigue in the Phase 3 TITAN Study
(
- Contribution to journal › Article
-
Mark
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer : Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
2021) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39(20). p.2294-2303(
- Contribution to journal › Article
- 2019
-
Mark
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN) : a randomised, placebo-controlled, phase 3 study
(
- Contribution to journal › Article
-
Mark
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
(
- Contribution to journal › Article
- 2009
-
Mark
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
(
- Contribution to journal › Article